PROCAINAMIDE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Procainamide Hydrochloride patents expire, and when can generic versions of Procainamide Hydrochloride launch?
Procainamide Hydrochloride is a drug marketed by Ani Pharms, Ascot, Ivax Sub Teva Pharms, Lannett, Lederle, Roxane, Vangard, Watson Labs, Abraxis Pharm, Hospira, Intl Medication, Nexus, Pharmafair, Smith And Nephew, Solopak, Warner Chilcott, West-ward Pharms Int, Inwood Labs, and Sandoz. and is included in fifty-eight NDAs.
The generic ingredient in PROCAINAMIDE HYDROCHLORIDE is procainamide hydrochloride. There are nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Procainamide Hydrochloride
A generic version of PROCAINAMIDE HYDROCHLORIDE was approved as procainamide hydrochloride by INTL MEDICATION on July 31st, 1984.
Summary for PROCAINAMIDE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 19 |
NDAs: | 58 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Clinical Trials: | 16 |
Patent Applications: | 1,256 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PROCAINAMIDE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for PROCAINAMIDE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Abant Izzet Baysal University | N/A |
Jeffrey Moak | Phase 4 |
Ottawa Hospital Research Institute | Phase 4 |
Pharmacology for PROCAINAMIDE HYDROCHLORIDE
Drug Class | Antiarrhythmic |